Janssen starts clinical trial with ebola vaccin

October 12, 2015 News Janssen Pharmaceutica

Janssen Pharmaceutica is starting the first field trials of the new Ebola vaccine in the affected regions in Sierra Leone. The pharmaceutical company wants to test whether the vaccine is safe and whether it enables the immune system to protect the body against ebola. The vaccine, in which Janssen puts a lot of effort since the outbreak in 2014, consists of two injections. It was developed by the subsidiary company Crucell and the Danish biotech partner Bavarian Nordic.

The Ebola virus took the lives of more than 11.000 West Africans in the last year and a half. Luckily, the epidemic is almost over. Still, pharmaceutical companies such as Janssen, GSK and Merck continue their research to be able to tackle a future epidemic much more quickly.

Learn more about the ebola vaccin in an interview with Janssen’s lead developper of the vaccin.

Avatar photo
Janssen Pharmaceutica

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

All posts

Subscribe to the BioVox newsletter